Heartening results: the CUPID gene therapy trial for heart failure.
作者信息
Giacca Mauro, Baker Andrew H
出版信息
Mol Ther. 2011 Jul;19(7):1181-2. doi: 10.1038/mt.2011.123.
Abstract
摘要
相似文献
1
Heartening results: the CUPID gene therapy trial for heart failure.
Mol Ther. 2011 Jul;19(7):1181-2. doi: 10.1038/mt.2011.123.
2
Design of a phase 2b trial of intracoronary administration of AAV1/SERCA2a in patients with advanced heart failure: the CUPID 2 trial (calcium up-regulation by percutaneous administration of gene therapy in cardiac disease phase 2b).
JACC Heart Fail. 2014 Feb;2(1):84-92. doi: 10.1016/j.jchf.2013.09.008. Epub 2014 Jan 25.
3
Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure.
Circulation. 2011 Jul 19;124(3):304-13. doi: 10.1161/CIRCULATIONAHA.111.022889. Epub 2011 Jun 27.
4
Sarcoendoplasmic reticulum calcium transport ATPase 2a: a potential gene therapy target in heart failure.
Cardiol Rev. 2013 May-Jun;21(3):151-4. doi: 10.1097/CRD.0b013e3182749cdb.
5
Sarcoplasmic reticulum and calcium cycling targeting by gene therapy.
Gene Ther. 2012 Jun;19(6):596-9. doi: 10.1038/gt.2012.34. Epub 2012 May 17.
6
New insights into SERCA2a gene therapy in heart failure: pay attention to the negative effects of B-type natriuretic peptides.
J Med Genet. 2018 May;55(5):287-296. doi: 10.1136/jmedgenet-2017-105120. Epub 2018 Feb 24.
7
Randomized Clinical Trials of Gene Transfer for Heart Failure with Reduced Ejection Fraction.
Hum Gene Ther. 2017 May;28(5):378-384. doi: 10.1089/hum.2016.166. Epub 2017 Mar 16.
8
Molecular targets in heart failure gene therapy: current controversies and translational perspectives.
Ann N Y Acad Sci. 2012 Apr;1254:42-50. doi: 10.1111/j.1749-6632.2012.06520.x.
9
Gene therapy for heart failure.
J Cardiol. 2015 Sep;66(3):195-200. doi: 10.1016/j.jjcc.2015.02.006. Epub 2015 Mar 25.
10
Gene therapy for heart failure: an investigational treatment that is coming of age.
Rev Esp Cardiol. 2010 Feb;63(2):137-40. doi: 10.1016/s1885-5857(10)70030-x.
引用本文的文献
1
Regulatory and Scientific Advancements in Gene Therapy: State-of-the-Art of Clinical Applications and of the Supporting European Regulatory Framework.
Front Med (Lausanne). 2017 Oct 26;4:182. doi: 10.3389/fmed.2017.00182. eCollection 2017.
2
Optogenetic stimulation of Drosophila heart rate at different temperatures and Ca2+ concentrations.
Physiol Rep. 2016 Feb;4(3). doi: 10.14814/phy2.12695.
3
A specifically designed nanoconstruct associates, internalizes, traffics in cardiovascular cells, and accumulates in failing myocardium: a new strategy for heart failure diagnostics and therapeutics.
Eur J Heart Fail. 2016 Feb;18(2):169-78. doi: 10.1002/ejhf.463. Epub 2016 Jan 7.
4
New Targets in the Drug Treatment of Heart Failure.
Drugs. 2016 Feb;76(2):187-201. doi: 10.1007/s40265-015-0498-3.
5
Gene- and cell-based bio-artificial pacemaker: what basic and translational lessons have we learned?
Gene Ther. 2012 Jun;19(6):588-95. doi: 10.1038/gt.2012.33.
本文引用的文献
1
Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure.
Circulation. 2011 Jul 19;124(3):304-13. doi: 10.1161/CIRCULATIONAHA.111.022889. Epub 2011 Jun 27.
2
Heart disease and stroke statistics--2010 update: a report from the American Heart Association.
Circulation. 2010 Feb 23;121(7):e46-e215. doi: 10.1161/CIRCULATIONAHA.109.192667. Epub 2009 Dec 17.
Zotero 插件